{"schema_version":"secwatch.filing_event.v1","accession":"0001610618-24-000121","form_type":"8-K","ticker":null,"cik":"0001610618","company_name":"Cidara Therapeutics, Inc.","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.767561+00:00","generated_at":"2026-05-31T05:14:21.612858+00:00","sec_items":["2.05","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cidara cuts 30% of workforce, focuses on CD388 influenza program; Phase 2b planned Q3 2024","bullets":["Reduction of 20 employees (~30% of workforce); charges ~$1.2M for severance and benefits in Q4 2024.","Workforce reduction expected to be substantially completed by November 1, 2024.","Company will focus entirely on CD388 influenza candidate; no other clinical trials currently planned.","Phase 2b clinical trial of CD388 for influenza prevention expected to initiate in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001610618-24-000121","json":"https://secwatch.observer/filing/0001610618-24-000121.json","markdown":"https://secwatch.observer/filing/0001610618-24-000121.md","text":"https://secwatch.observer/filing/0001610618-24-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000121/0001610618-24-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000121/cdtx-20240909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:14:21.612858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98d3967594943d780b5909b4ae34a790d889ff53","claim":"Cidara Therapeutics, Inc. announced a restructuring with charges of approximately $1.2 million (20 employees).","evidence_excerpt":"its influenza product candidate. The Reduction is expected to be substantially completed by November 1, 2024. The Company estimates that it will incur charges of approximately $1.2 million for severance payments and employee benefits, primarily in the fourth quarter of 2024. Substantially all of the estimated charges are expected to result in future cash","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061824000121/0001610618-24-000121-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.2 million"},{"label":"Headcount","value":"20 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}